179 related articles for article (PubMed ID: 2989419)
1. Clinical efficacy of a herpes simplex subunit vaccine.
Cappel R; Sprecher S; De Cuyper F; De Braekeleer J
J Med Virol; 1985 Jun; 16(2):137-45. PubMed ID: 2989419
[TBL] [Abstract][Full Text] [Related]
2. Immune response to a DNA free herpes simplex vaccine in man.
Cappel R; Sprecher S; Rickaert F; de Cuyper F
Arch Virol; 1982; 73(1):61-7. PubMed ID: 6289778
[TBL] [Abstract][Full Text] [Related]
3. Herpes simplex virus type-2 glycoprotein-subunit vaccine: tolerance and humoral and cellular responses in humans.
Mertz GJ; Peterman G; Ashley R; Jourden JL; Salter D; Morrison L; McLean A; Corey L
J Infect Dis; 1984 Aug; 150(2):242-9. PubMed ID: 6088648
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes.
Stanberry LR; Bernstein DI; Burke RL; Pachl C; Myers MG
J Infect Dis; 1987 May; 155(5):914-20. PubMed ID: 3031173
[TBL] [Abstract][Full Text] [Related]
5. Herpes. Vaccines for HSV.
Stanberry LR
Dermatol Clin; 1998 Oct; 16(4):811-6, xiv. PubMed ID: 9891686
[TBL] [Abstract][Full Text] [Related]
6. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection.
Mertz GJ; Ashley R; Burke RL; Benedetti J; Critchlow C; Jones CC; Corey L
J Infect Dis; 1990 Apr; 161(4):653-60. PubMed ID: 2181031
[TBL] [Abstract][Full Text] [Related]
7. [Immunological shifts and effectiveness of vaccination in patients with recurrent herpetic stomatitis].
Shavrova EN; Bikbulatov RM; Aleksandrova LL; Khliustov SV; Sosnin GP
Vopr Virusol; 1987; 32(5):597-600. PubMed ID: 2829442
[TBL] [Abstract][Full Text] [Related]
8. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group.
Corey L; Langenberg AG; Ashley R; Sekulovich RE; Izu AE; Douglas JM; Handsfield HH; Warren T; Marr L; Tyring S; DiCarlo R; Adimora AA; Leone P; Dekker CL; Burke RL; Leong WP; Straus SE
JAMA; 1999 Jul; 282(4):331-40. PubMed ID: 10432030
[TBL] [Abstract][Full Text] [Related]
9. Vaccine induced HSV 1 antibodies fail to correlate with protection against HSV 2 in guinea pigs.
Welch MJ; Ridgeway PH; Phillpotts RJ
FEMS Microbiol Immunol; 1988 Dec; 1(3):157-62. PubMed ID: 2856207
[TBL] [Abstract][Full Text] [Related]
10. Antibody reactivity with Skinner HSV vaccine.
Muniu EM; Durham J; Shariff D; Hartley CE; Fuller A; Melling J; Wiblin C; Wilkins G; Buchan A; Skinner GR
Med Microbiol Immunol; 1987; 176(6):315-27. PubMed ID: 2828898
[TBL] [Abstract][Full Text] [Related]
11. Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D.
Berman PW; Gregory T; Crase D; Lasky LA
Science; 1985 Mar; 227(4693):1490-2. PubMed ID: 2983428
[TBL] [Abstract][Full Text] [Related]
12. Development of a herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use.
Burke RL
Rev Infect Dis; 1991; 13 Suppl 11():S906-11. PubMed ID: 1664126
[TBL] [Abstract][Full Text] [Related]
13. Prospects for control of herpes simplex virus disease through immunization.
Stanberry LR; Cunningham AL; Mindel A; Scott LL; Spruance SL; Aoki FY; Lacey CJ
Clin Infect Dis; 2000 Mar; 30(3):549-66. PubMed ID: 10722443
[TBL] [Abstract][Full Text] [Related]
14. Human antibody response to herpes simplex virus-specific polypeptides after primary and recurrent infection.
Kahlon J; Lakeman FD; Ackermann M; Whitley RJ
J Clin Microbiol; 1986 Apr; 23(4):725-30. PubMed ID: 2422204
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent, and latent genital infections with herpes simplex virus type 2 in guinea pigs.
Berman PW; Vogt PE; Gregory T; Lasky LA; Kern ER
J Infect Dis; 1988 May; 157(5):897-902. PubMed ID: 2834467
[TBL] [Abstract][Full Text] [Related]
16. Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs.
Simms JR; Heath AW; Jennings R
J Infect Dis; 2000 Apr; 181(4):1240-8. PubMed ID: 10762560
[TBL] [Abstract][Full Text] [Related]
17. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM
J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292
[TBL] [Abstract][Full Text] [Related]
18. Immune responses to DNA free herpes simplex proteins in man.
Cappel R; Sprecher S; de Cuyper F
Dev Biol Stand; 1982; 52():345-50. PubMed ID: 6299843
[TBL] [Abstract][Full Text] [Related]
19. Recurrences after oral and genital herpes simplex virus infection. Influence of site of infection and viral type.
Lafferty WE; Coombs RW; Benedetti J; Critchlow C; Corey L
N Engl J Med; 1987 Jun; 316(23):1444-9. PubMed ID: 3033506
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of HSV-1 ISCOM vaccine in the guinea-pig model of HSV-2 infection.
Erturk M; Phillpotts RJ; Welch MJ; Jennings R
Vaccine; 1991 Oct; 9(10):728-34. PubMed ID: 1661978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
